Department of Radiology Copenhagen University Hospital Herlev
Copenhagen, Denmark
NCT Number: NCT00332943
The purpose of this study is to determine whether Barium or BariumFerumoxsil is better for fecal tagging in MR colonography. Patients referred to colonoscopy are offered MR colonography before colonoscopy. Two days before colonography, patients ingest either a contrast agent A (200 ml Barium sulphate solution 1g/ml)) four times a day or a 200 ml contrast agent B (Barium sulfate(25%) and Ferumoxil(75%)) four times a day, which will render fecal masses "invisible" on the following MR colonography. The patients are randomised to either contrast agent A or B. The examinations are evaluated by two independent blinded readers, who will rate the tagging quality of the contrast agents. The quality of tagging will be rated by a Visual Analog Scale (VAS) and Relative contrast (ReCon = Iwall - Ilumen/ Iwall + Ilumen).
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 4
Copenhagen, Denmark
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Herlev Hospital
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03488537
Colonic Diseases, Colorectal Cancer
Enschede, Twente, Netherlands
View Trial DetailsNCT00272324
Adenoma, Adenomas
Los Angeles, California, United States
View Trial DetailsNCT03146520
Colonic Diseases, Colorectal Cancer
Seoul, South Korea
View Trial DetailsNCT01917513
Adenoma, Colonic Diseases
Boston, Massachusetts, United States
View Trial Details